ABSTRACT In 19 asthmatic children, aged 2-6 years, the effect of six weeks' treatment with inhaled budesonide or placebo on functional residual capacity (FRC-helium dilution) and bronchodilator responsiveness was assessed in a double blind, randomised crossover trial. FRC was increased in most children at the start oftreatment. Treatment with budesonide was associated with a reduction in FRC by comparison with placebo (median change 9% v 0%; p < 0 05). There was a trend towards a greater response to a bronchodilator after budesonide. The results suggest that inhaled corticosteroids reduce hyperinflation in young asthmatic children.
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Measurement of functional residual capacity (FRC) by helium gas dilution is accurate and reproducible in young children.' Most asthmatic children have hyperinflation2 and, although this can be reduced acutely by bronchodilator treatment,3 though not usually to normal, a pilot study' suggested this hyperinflation may persist for many months. The effect of chronic hyperinflation on lung function is not known but it may be associated with respiratory problems persisting into adulthood. 5 Budesonide, a topically active corticosteroid, can be delivered by a large volume spacer to young children' and a recent study has shown it to be of clinical benefit to young asthmatic patients.7 Our aim was to investigate whether inhaled budesonide influenced hyperinflation and bronchodilator responsiveness, assessed as change in FRC, in young asthmatic children.
Methods
Budesonide, 200 pg twice daily, and placebo were given in random order via a large volume spacing device (Nebuhaler)' for six weeks in a double blind crossover trial, as described elsewhere.! At the beginning and end of each treatment period the children attended the paediatric respiratory laboratory between 8 and 10 am. The last dose ofbudesonide or placebo was administered on the previous evening and inhaled bronchodilator treatment was withheld for at least two hours before pulmonary function testing. Accepted 22 August 1988 height. As the mean coefficient of variation for the measurement of FRC is 4% we compared the number of children who showed a fall greater than 8% of that predicted for height. FRC was measured before and 10 minutes after 500 ug terbutaline given by Nebuhaler at the beginning and end of each treatment (eight measurements in total) in 19 children. Ten children (five of them boys; mean age 4-4 years) received placebo first and nine (seven of them boys; mean age 4-6 years) budesonide first.
Permission for the study was granted by the King's College Hospital ethics committee and informed consent was obtained from the parents.
FRC measurements were examined for an "order" and "carry over" effect. 
Results
FRC before bronchodilator did not differ significantly at the beginning of the first and second treatment periods: median 129% (range 51-219%) first leg; median 118% (range 88-199%) second leg. There was no carry over or order effect, so the results from the two legs were analysed together.
More children had FRC values at least 8% lower after budesonide (13 of 19) than after placebo (4 of 19) (p < 0-01).
There was a greater fall in FRC after budesonide (median change -9%, range -90% to + 33%) than after placebo (median change 0%, range -47% to + 51%; p < 005) (fig) . Twelve of 19 children showed a fall in FRC of more than 8% after terbutaline at the end of each treatment period. Overall, bronchodilator responsiveness tended to be greater after treatment with budesonide (median change in FRC -6%, range -47% to + 31%) than after placebo (median range 0%, range -46% to + 43%), though the difference was not significant. FRC tended to be lower after budesonide (median 112%, range 86%-158%) than after placebo (median 134%, range 74%-164%), though the difference was not significant. 
